Summit Therapeutics (SMMT) Other Non-Current Liabilities (2019 - 2026)

Summit Therapeutics (SMMT) has reported Other Non-Current Liabilities for 8 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• Quarterly Other Non-Current Liabilities fell 1.96% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 million (down 1.96% YoY) and the FY2025 annual result came in at $1.8 million, up 12.39% from the prior year.
• Other Non-Current Liabilities was little changed at $1.8 million in Q2 2026 per SMMT's latest filing, from $1.8 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for SMMT reached as high as $3.3 million in Q1 2024 and fell as low as $1.4 million in Q4 2022.
• A 5-year average of $1.9 million and a median of $1.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 48.52% — and 2024, when it jumped 123.5%.
• Year by year, Other Non-Current Liabilities stood at $1.4 million in 2022, then increased by 9.31% to $1.6 million in 2023, then climbed by 4.35% to $1.6 million in 2024, then climbed by 12.39% to $1.8 million in 2025, then dropped by 1.64% to $1.8 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.8 million, $1.8 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.